Cas9 News and Research

RSS

New CRISPR system selectively destroys cancer cells

Among the challenges in treating disease, including cancer, is wiping out malignancies, infection, contaminants or other pathologies, without destroying healthy tissue.

6 May 2026

New human cell model replicates key mechanisms of neurodegenerative diseases

Researchers at LMU have developed a human cell model that replicates key mechanisms of neurodegenerative diseases - with potential for novel therapies.

23 Apr 2026

New CRISPR tool selectively cuts tumor DNA while sparing healthy cells

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells.

15 Apr 2026

New method boosts AI-driven protein engineering with massive data

Protein engineering is a field primed for artificial intelligence research. Each protein is made up of amino acids; to optimize a protein function, researchers modify proteins by switching out one of 20 different amino acids for another.

13 Apr 2026

Pseudogene lncRNAs regulate cancer stem cell behavior and signaling

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy due to their innate capacity for self-renewal and differentiation.

11 Apr 2026

Non-clinical safety assessment crucial for CRISPR-based gene therapies

The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling precise correction, disruption, and regulation of disease-associated genes.

10 Apr 2026

Adding three simple amino acids boosts mRNA and CRISPR delivery

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution.

12 Mar 2026

Review: Pathogenesis, diagnosis, and management of harlequin ichthyosis

Harlequin ichthyosis (HI) is a rare, severe genetic skin disorder caused by ABCA12 mutations, leading to defective lipid transport and loss of skin barrier function.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Engineered wax moths offer ethical alternative to rodents used in research

A scientific breakthrough not only promises faster testing for antimicrobial resistance, but also an ethical solution to the controversial issue of using rodents in research.

10 Feb 2026

Advancing brain microphysiological systems for in vitro neurotoxicity and cognitive function testing

Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling.

From Yokogawa Life Science 3 Feb 2026

ERC Proof of Concept grant supports promising CRISPR-based cancer treatment research

Microbiologist John van der Oost of Wageningen University & Research (WUR) has received an ERC Proof of Concept grant to further develop a promising CRISPR-based approach to cancer treatment. With funding of €150,000, he and researcher Christian Südfeld will spend the next eighteen months working on a method to kill cancer cells from within, while sparing healthy cells as much as possible.

30 Jan 2026

Purdue researchers discover new therapeutic target for triple-negative breast cancer

A Purdue University team led by Kyle Cottrell has discovered a new therapeutic target for triple-negative breast cancer.

27 Jan 2026

ELRIG announces Drs Stephen Ward and Annarita Miccio as keynote speakers for Cell and Gene Therapy 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speakers for Cell and Gene Therapy 2026. Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute) will lead the inaugural two-day event taking place at Hinxton Hall in Cambridge, UK from 9-10 March.

20 Jan 2026

CRISPR-Cas3: A safer gene-editing tool shows promise for transthyretin amyloidosis treatment

Genetic disorders occur due to alterations in the primary genetic material, deoxyribonucleic acid (DNA), of an organism. Transthyretin amyloidosis (ATTR) is a progressive disorder involving amyloid deposits of misfolded transthyretin (TTR) proteins.

14 Jan 2026

CIRM awards $7.4 million to advance stem cell-based gene therapy for Friedreich's ataxia

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for Friedreich's ataxia, a rare inherited neurodegenerative disease that causes progressive loss of coordination, muscle strength, heart function and overall mobility.

8 Jan 2026

CRISPR Cas12a3: A precise tool to halt viral protein production

Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most known CRISPR systems target invading pathogens' DNA and chop it up to disable and modify genes, heading off infections at the (cellular) pass.

7 Jan 2026

New method can help better assess precision genome editing technology

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources spent improving CRISPR gene editing technology focus on identifying small off-target sites that pose a safety risk, which is also technically challenging.

2 Jan 2026

Study identifies TAK1 gene as a key brake on cancer immunotherapy

Australian researchers have discovered that the TAK1 gene helps cancer cells survive attack from the immune system, revealing a mechanism that may limit the effectiveness of immunotherapy treatments.

19 Dec 2025

Advances in hemophilia gene therapy bring hope for pediatric patients

In the past three years, gene therapy has reshaped what's possible in hemophilia treatment for patients 18 and older. But a key question remains: How soon will these advances reach children?

18 Dec 2025